Remdesivir approved to treat COVID in Infants, yet Vitamin D is 3000 X more cost effective and widely used
FDA Rubber-Stamps Remdesivir for Infants Without Evidence of Safety, Efficacy
"According to the press release, the FDA’s decision to approve the therapy, marketed under the name Veklury, is supported by a clinical study conducted on infants 4 weeks and older weighing a minimum of 6.6 pounds."
"The study is underway and will not be completed until February 2023 . There are no published results."
"However, Gilead Sciences, maker of remdesivir and sponsor of the study, provided the following details in a company press release :"
A total of 53 hospitalized pediatric patients were enrolled in the clinical study.
72% suffered adverse events.
21% suffered serious adverse events determined to be unrelated to the drug.
Three children died from either underlying conditions or COVID-19.
Note: Gilead saw $5.6B in remdesivir sales in 2021
Assuming $3,100 per dose, Gilead sold 1.8 million doses in 2022
Well over 1 billion doses of vitamin D were sold in 2022
Remdesivir ‘Disastrous’ as COVID Treatment, But Government Pays Hospitals to Use It - May 2022
"Remdesivir, which to this day is the primary COVID drug approved for use in U.S. hospitals, routinely causes severe organ damage and, often, death."
"Despite its horrible track record, the U.S. government actually pays hospitals a 20% upcharge for sticking to the remdesivir protocol, plus an additional bonus. Hospitals must also use remdesivir if they want liability protection."
**_
"Safety and effectiveness ... have not been established in pediatric patients younger than 12 years of age" (package insert)* Natural Health May 2, 2022 *---
VitaminDWiki - Risk factors for severe COVID in children are all related to low vitamin D (same as adults) - April 2022
VitaminDWiki - Children with higher Vitamin D had less severe COVID (no surprise) – April 2022
VitaminDWiki - Severe pediatric COVID 5.5 more likely if low vitamin D (review of 6 studies) -July 2021
VitaminDWiki - Vitamin D might reduce Multisystem Inflammatory Syndrome in children – March 2021
Vitamin D is 3000 X more cost-effective, studied on 16X more patients, with virtually no side effects however, Gilead Sciences had the money to petition for the FDA approval* 5,000 X ROI for Gilead Sciences ($5,000 of profit for every $1 invested) *Guessing: $1 billion in profit in 2 years for $200,000 cost (trial + FDA petition)
Probably would cost $50,000 to petition the FDA that Vitamin D can reduce COVID risk in children
- FDA allows the claim that Vitamin D “supports healthy pregnancies and promotes full-term births” – Oct 2019* Unfortunately, there are >100 Vitamin D suppliers,. so the additional total Vitamin D sales ($3 million?) would be greatly deluted ** Addional sales:<$3 million *$1 of vitamin D per infected child X 24 million children X 1 in 10 are infected
Guess increased profit = 20% X increased sales = $600,000
Ther might be a single manufactuer that has 5% of the market - it would get increased revenue of $30,000
This would not repay the $50,000 cost to petition the FDA
Many successful vitamin D early treatment trials for adults
Vitamin D is much better than Remdesivir for adults* https://c19early.com/#fpearly *
---* https://c19rmd.com/ *
VitaminDWiki - Infant-Child category has studies and starts with
{include}
{include}
VitaminDWiki pages with FDA in the title (35 as of April 2022)
This list is automatically updated
{LIST()}** Title change made April 2022 caused the visitor count to reset.
There have actually been visitors to this page since it was originally made__